Why A Covid-19 Vaccine Won't Halt Feverish Demand For Coronavirus Tests

You'd think that, as biopharma companies close in on an effective vaccine against Covid-19, the days of widespread coronavirus tests are numbered.

Not so fast, analysts say. When Abbott Laboratories (ABT) recently reported triple-digit growth in second-quarter diagnostics, that gave the investment community pause. Now, Wall Street believes Abbott won't be the only diagnostics player to benefit as U.S. Covid-19 cases mushroom.